Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial


Condition: Prostate Cancer Metastatic

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT03655886

Sponsor: University Hospital, Ghent

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Male ≥18y
  • Histologically proven PC
  • Newly diagnosed metastatic PC as assessed by standard imaging (CT and bone scintigraphy)
  • ECOG 0-1 (2 if related to local PC symptoms)
  • Eligible for local treatment
  • Written informed consent and able and willing to comply with protocol requirements

Exclusion Criteria:

  • Previous systemic treatment for PC except ADT started within 3 months before randomization
  • Previous radiotherapy to the pelvis interfering with prostate irradiation
  • Previous surgery in the pelvis interfering with radical prostatectomy
  • Symptoms related to metastatic lesions, persisting for at least 2 weeks after initiation of ADT
  • Metastatic brain disease, leptomeningeal disease or imminent spinal cord compression
  • Previous or current malignant disease which is likely to interfere with LoMP II treatment or assessment
  • Psychological disorder intervening with understanding the information or the informed consent

View trial on ClinicalTrials.gov


email news signup